Efficacy of Recombinant Human Thrombopoietin Combined with Rituximab in the Treatment of Immune Thrombocytopenia and Its Influence on Coagulation Function and Adverse Reactions
LIU Dan, FU Xiangjun, CHEN Wenting, et al
Hainan General Hospital / Hainan Hospital Affiliated to Hainan Medical College, Hainan Haikou 570311, China
Abstract：Objective: To explore the efficacy of recombinant human thrombopoietin (rhTPO) combined with rituximab in the treatment of immune thrombocytopenia (ITP) and its influence on coagulation function and adverse reactions. Methods: A total of 198 patients with ITP in our hospital were retrospectively analyzed, and they were grouped according to the treatment regimens. Propensity score matching was conducted according to the general data of patients, and finally 61 cases in control group and 63 cases in study group with balanced general data were obtained. Control group was treated with rituximab, and observation group was treated with rhTPO combined with rituximab. The clinical efficacy, platelet count (PLT), coagulation function and adverse reactions were compared between the two groups. Results: After treatment, the clinical total effective rate was 68.85% in study group and 80.95% in control group (P>0.05), but the complete response rate of patients in study group was significantly higher than that in control group (P<0.05), and the onset time was significantly shorter than that in control group (P<0.05). The PLT levels after 1 week, 2 weeks, 4 weeks, 8 weeks and 12 weeks of treatment in the two groups were all higher than those before treatment (P<0.05), and the PLT levels in study group after 2 weeks, 4 weeks, 8 weeks and 12 weeks of treatment were higher than those in control group (P<0.05). Before and after treatment, there were no significant differences in the levels of activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen (FIB) between the two groups (P>0.05), and there were no statistically significant differences in the levels of indicators between the groups (P>0.05). During treatment, there was no significant difference in the incidence rate of adverse reactions between control group and observation group (19.67% vs 25.40%) (P>0.05). Conclusion: RhTPO combined with rituximab has a significant efficacy in the treatment of ITP. It can increase the level of PLT in a short period of time, and it does not adversely affect the coagulation function, with clinical safety of medication.
刘丹, 符祥俊, 陈文婷, 孟灿. 重组人血小板生成素联合利妥昔单抗治疗免疫性血小板减少症疗效及对凝血功能和不良反应的影响[J]. 河北医学, 2021, 27(8): 1256-1260.
LIU Dan, FU Xiangjun, CHEN Wenting, et al. Efficacy of Recombinant Human Thrombopoietin Combined with Rituximab in the Treatment of Immune Thrombocytopenia and Its Influence on Coagulation Function and Adverse Reactions. HeBei Med, 2021, 27(8): 1256-1260.
2021, Vol. 27 
冀公网安备13080202000677号